Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.
Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores
Maria Elisa de Oliveira Lanna, Maria Lucia Vellutini Pimentel and Sergio Augusto Pereira Novis
Insulin resistance, hyper-insulinemia and products associated to insulin metabolism can affect the amyloid cascade and promote the onset of Alzheimer`s disease or aggravate the condition, in early or old age regardless of the development of type 2 diabetes. The changes described in pathological studies and molecular research, classify two types of mechanism involved with cognitive impairment in these cases: one related to cerebrovascular events due the action of vascular risk factors, and the other more controversial, non-cerebrovascular mechanism involving the interaction of insulin with Aβ in the entorhinal cortex and hippocampus, as well as its synaptogenesis action that involves signaling of intracellular molecular paths in the modulating of neurotransmitters such as acetylcholine, norepinephrine and glutamate receptors. Based on a literature review, the role of insulin in the Central Nervous System is examined along with its participation in the amyloidogenesis process in progression to Alzheimer Disease. This review also addresses the consequence of chronic peripheral hyperinsulinemia, leading to down-regulation of insulin receptors in the blood-brain barrier and decreased insulin up-take, causing a state of central hypoinsulinism. This state interferes mainly in the process of Aβ degradation, emphasizing the role of the catalytic enzymes in Aβ clearance, particularly of the insulinase. Among others, increasing synaptic toxicity by disrupting PI3K/Akt inhibition of the GSK3 intracellular molecular pathway increasing tau phosphorylation, as well as PKC synaptogenesis signaling, causing clinical and anatomic changes that favor Alzheimer Disease.